Stem Cell Treatment
Total Trials
15
As Lead Sponsor
9
As Collaborator
6
Total Enrollment
731
NCT00703339
Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
Phase: Phase 2
Role: Lead Sponsor
Start: Jun 30, 2008
Completion: Dec 31, 2009
NCT00781885
A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients
Start: Jan 31, 2009
Completion: Sep 30, 2010
NCT00792571
An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients
Start: Feb 28, 2009
Completion: Nov 30, 2013
NCT00990314
Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients
Start: Nov 30, 2009
NCT00989963
Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)
Start: Feb 1, 2010
Completion: Sep 13, 2011
NCT01458236
A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor
Phase: Phase 3
Start: Nov 30, 2011
Completion: Mar 31, 2016
NCT01908699
Beraprost-314d Added-on to Tyvaso® (BEAT)
Start: May 31, 2013
Completion: Feb 19, 2019
NCT01966302
Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)
Role: Collaborator
Start: Nov 30, 2013
Completion: Jun 2, 2019
NCT03657095
A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension
Start: Dec 10, 2018
Completion: Jul 20, 2019
NCT03794583
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Start: Dec 21, 2018
Completion: Nov 29, 2022
NCT03888365
Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH
Phase: N/A
Start: Apr 1, 2019
Completion: Sep 19, 2019
NCT04365101
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
Phase: Phase 1/2
Start: May 13, 2020
Completion: Jun 30, 2022
NCT04627428
Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)
Start: Apr 5, 2022
Completion: Dec 1, 2026
NCT05203510
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
Phase: Phase 4
Start: Oct 20, 2022
Completion: Apr 30, 2028
NCT05340426
Porcine Kidney Xenotransplantation in Patients With End-Stage Kidney Disease
Phase: Phase 1
Start: Jan 31, 2024
Completion: Jun 30, 2029
Loading map...